First in-human study of drug targeting brain inflammation supports further development
MW189 blocks abnormal inflammation in the brain that is known to contribute to injury- and disease-induced neurologic impairments in a number of acute and chronic brain disorders. This study examined MW189 in healthy adult volunteers.
The article reports that MW189 was safe and well-tolerated by volunteers, with no clinically significant concerns after either a single dose or multiple administrations of MW189. "This is an important result," said Van Eldik, "because in order to get future FDA approval of any drug for patients, the drug candidate first has to be tested and shown to be safe in healthy volunteers." Van Eldik goes on to say "overall, these studies support further development of MW189 for treatment of patients with acute brain injuries such as TBI or hemorrhagic stroke."
For more details: https://pharmacology.healthconferences.org/webinar
Contact: pharmafroum@theexpertsmeet.com
Whats app: +44 7426056247
No comments:
Post a Comment